e484 k mutation enable virus escape people immune responses 28 december preprint team led immunologist rino rappuoli fondazione toscana life sciences siena italy grew sars cov-2 presence low levels person convalescent serum goal select viral mutations evade diverse repertoire antibodies generated response infection experiment not necessarily supposed work says mclellan co author 90 days virus picked 3 mutations impervious person serum including e484 k mutation south african variant n terminal domain changes found uk variant surprising says mclellan suggested individual entire antibody response sars cov-2 directed small portion spike protein lab evolved strain proved resistant convalescent sera people experiment suggests